# Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

> **NCT04071223** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 134 (estimated)

## Conditions studied

- Advanced Renal Cell Carcinoma
- Chromophobe Renal Cell Carcinoma
- Clear Cell Renal Cell Carcinoma
- Collecting Duct Carcinoma
- Kidney Medullary Carcinoma
- Metastatic Malignant Neoplasm in the Bone
- Papillary Renal Cell Carcinoma
- Stage IV Renal Cell Cancer AJCC v8
- Unclassified Renal Cell Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Scan
- **DRUG:** Cabozantinib S-malate
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Questionnaire Administration
- **RADIATION:** Radium Ra 223 Dichloride

## Key facts

- **NCT ID:** NCT04071223
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-29
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04071223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04071223, "Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT04071223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*